VERTEX PHARMACEUTICALS INC (VX1.DE) Fundamental Analysis & Valuation
FRA:VX1 • US92532F1003
Current stock price
This VX1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. VX1.DE Profitability Analysis
1.1 Basic Checks
- In the past year VX1 was profitable.
- In the past year VX1 had a positive cash flow from operations.
- Of the past 5 years VX1 4 years were profitable.
- VX1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- VX1's Return On Assets of 15.42% is amongst the best of the industry. VX1 outperforms 92.41% of its industry peers.
- Looking at the Return On Equity, with a value of 21.18%, VX1 belongs to the top of the industry, outperforming 91.14% of the companies in the same industry.
- VX1's Return On Invested Capital of 15.14% is amongst the best of the industry. VX1 outperforms 94.94% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for VX1 is above the industry average of 11.35%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| ROIC | 15.14% |
1.3 Margins
- The Profit Margin of VX1 (32.94%) is better than 93.67% of its industry peers.
- In the last couple of years the Profit Margin of VX1 has declined.
- The Operating Margin of VX1 (39.04%) is better than 92.41% of its industry peers.
- VX1's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 86.24%, VX1 is in the better half of the industry, outperforming 74.68% of the companies in the same industry.
- In the last couple of years the Gross Margin of VX1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.04% | ||
| PM (TTM) | 32.94% | ||
| GM | 86.24% |
2. VX1.DE Health Analysis
2.1 Basic Checks
- VX1 has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- The number of shares outstanding for VX1 has been reduced compared to 1 year ago.
- The number of shares outstanding for VX1 has been reduced compared to 5 years ago.
- Compared to 1 year ago, VX1 has an improved debt to assets ratio.
2.2 Solvency
- VX1 has an Altman-Z score of 11.47. This indicates that VX1 is financially healthy and has little risk of bankruptcy at the moment.
- The Altman-Z score of VX1 (11.47) is better than 87.34% of its industry peers.
- The Debt to FCF ratio of VX1 is 0.03, which is an excellent value as it means it would take VX1, only 0.03 years of fcf income to pay off all of its debts.
- VX1 has a better Debt to FCF ratio (0.03) than 98.73% of its industry peers.
- VX1 has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
- VX1's Debt to Equity ratio of 0.01 is amongst the best of the industry. VX1 outperforms 88.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 11.47 |
2.3 Liquidity
- VX1 has a Current Ratio of 2.90. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 2.90, VX1 is doing good in the industry, outperforming 60.76% of the companies in the same industry.
- VX1 has a Quick Ratio of 2.46. This indicates that VX1 is financially healthy and has no problem in meeting its short term obligations.
- VX1 has a Quick ratio (2.46) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.9 | ||
| Quick Ratio | 2.46 |
3. VX1.DE Growth Analysis
3.1 Past
- VX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 6248.28%, which is quite impressive.
- Measured over the past years, VX1 shows a quite strong growth in Earnings Per Share. The EPS has been growing by 12.27% on average per year.
- The Revenue has grown by 8.90% in the past year. This is quite good.
- Measured over the past years, VX1 shows a quite strong growth in Revenue. The Revenue has been growing by 14.10% on average per year.
3.2 Future
- The Earnings Per Share is expected to grow by 12.36% on average over the next years. This is quite good.
- Based on estimates for the next years, VX1 will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. VX1.DE Valuation Analysis
4.1 Price/Earnings Ratio
- VX1 is valuated rather expensively with a Price/Earnings ratio of 23.67.
- Based on the Price/Earnings ratio, VX1 is valued cheaper than 82.28% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 26.91, VX1 is valued at the same level.
- Based on the Price/Forward Earnings ratio of 22.48, the valuation of VX1 can be described as rather expensive.
- Based on the Price/Forward Earnings ratio, VX1 is valued cheaply inside the industry as 83.54% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 23.69, VX1 is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.67 | ||
| Fwd PE | 22.48 |
4.2 Price Multiples
- VX1's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VX1 is cheaper than 81.01% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, VX1 is valued cheaper than 82.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 34.66 | ||
| EV/EBITDA | 20.19 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- VX1 has a very decent profitability rating, which may justify a higher PE ratio.
5. VX1.DE Dividend Analysis
5.1 Amount
- VX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
VX1.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:VX1 (4/8/2026, 7:00:00 PM)
377.1
+7.95 (+2.15%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.67 | ||
| Fwd PE | 22.48 | ||
| P/S | 9.22 | ||
| P/FCF | 34.66 | ||
| P/OCF | 30.49 | ||
| P/B | 5.93 | ||
| P/tB | 6.45 | ||
| EV/EBITDA | 20.19 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 15.42% | ||
| ROE | 21.18% | ||
| ROCE | 21.51% | ||
| ROIC | 15.14% | ||
| ROICexc | 24.16% | ||
| ROICexgc | 27.17% | ||
| OM | 39.04% | ||
| PM (TTM) | 32.94% | ||
| GM | 86.24% | ||
| FCFM | 26.61% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 208.58% | ||
| Cap/Sales | 3.65% | ||
| Interest Coverage | 377.85 | ||
| Cash Conversion | 74.18% | ||
| Profit Quality | 80.79% | ||
| Current Ratio | 2.9 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z | 11.47 |
VERTEX PHARMACEUTICALS INC / VX1.DE Fundamental Analysis FAQ
What is the ChartMill fundamental rating of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
ChartMill assigns a fundamental rating of 7 / 10 to VX1.DE.
What is the valuation status for VX1 stock?
ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VX1.DE). This can be considered as Fairly Valued.
How profitable is VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 23.67 and the Price/Book (PB) ratio is 5.93.
Can you provide the expected EPS growth for VX1 stock?
The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 5.3% in the next year.